Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.
2.

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

Strasser A, Harris AW, Bath ML, Cory S.

Nature. 1990 Nov 22;348(6299):331-3.

PMID:
2250704
3.

The transgenic window on lymphoid malignancy.

Adams JM, Harris AW, Vaux DL, Alexander WS, Rosenbaum H, Klinken SP, Strasser A, Bath ML, McNeall J, Cory S.

Princess Takamatsu Symp. 1989;20:297-309.

PMID:
2518688
4.

Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.

Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ.

J Immunol. 1990 May 1;144(9):3602-10.

PMID:
2184193
7.

Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity.

Tomlin JL, Guinn BA, Penn LZ, Berinstein NL.

Leuk Lymphoma. 2005 Apr;46(4):581-92.

PMID:
16019487
8.

Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells.

Cory S, Harris AW, Strasser A.

Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):289-95. Review.

PMID:
7846127
9.

Lymphoid neoplasia and the control of haemopoietic differentiation.

Adams JM, Harris AW, Langdon WY, Klinken SP, Kongsuwan K, Alexander WS, Hariharan I, Vaux D, Rosenbaum H, Crawford M, et al.

Ciba Found Symp. 1989;142:54-64; discussion 65-70.

PMID:
2568245
10.

Transformation of growth factor-dependent myeloid stem cells with retroviral vectors carrying c-myc.

Green SM, Lowe AD, Parrington J, Karn J.

Oncogene. 1989 Jun;4(6):737-51.

PMID:
2660072
11.

Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.

Zörnig M, Busch G, Beneke R, Gulbins E, Lang F, Ma A, Korsmeyer S, Möröy T.

Oncogene. 1995 Nov 16;11(10):2165-74.

PMID:
7478538
12.

Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice.

Jacobsen KA, Prasad VS, Sidman CL, Osmond DG.

Blood. 1994 Oct 15;84(8):2784-94.

13.

Oncogenic co-operation in beta-cell tumorigenesis.

Pelengaris S, Khan M.

Endocr Relat Cancer. 2001 Dec;8(4):307-14. Review.

15.
16.

Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro.

Cleveland JL, Jansen HW, Bister K, Fredrickson TN, Morse HC 3rd, Ihle JN, Rapp UR.

J Cell Biochem. 1986;30(3):195-218.

PMID:
3084503
17.
18.

Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.

Shinto Y, Morimoto M, Katsumata M, Uchida A, Aozasa K, Okamoto M, Kurosawa T, Ochi T, Greene MI, Tsujimoto Y.

Oncogene. 1995 Nov 2;11(9):1729-36.

PMID:
7478600
19.

IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.

Möröy T, Fisher P, Guidos C, Ma A, Zimmerman K, Tesfaye A, DePinho R, Weissman I, Alt FW.

EMBO J. 1990 Nov;9(11):3659-66.

20.

Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.

Langdon WY, Harris AW, Cory S.

Oncogene Res. 1988;3(3):271-9.

PMID:
3144697

Supplemental Content

Support Center